Mylan (MYL): Biocon's Bangalore Facility Re-Inspections Likely Not Required, Observations Benign - Guggenheim

Guggenheim analyst Rohit Vanjani weighed in on Mylan (NASDAQ: MYL) after they were able to FOIA the Form 483 issued to Biocon's Bangalore facility (attached) where biosimilar Neulasta is being manufactured and speak to a consultant regarding the observations.

"We previously provided different consultant perspectives without having the Form 483, where the feedback was that Mylan would still likely get an on-time approval," Vanjani notes. "After reviewing the observations in more detail and following up with a consultant, we are reiterating our view that a re-inspection likely is not required and that the observations are benign."

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• Banner Corporation (BANR) PT Lowered to $51 at Piper Sandler